JP2023504271A5 - - Google Patents
Info
- Publication number
- JP2023504271A5 JP2023504271A5 JP2022532766A JP2022532766A JP2023504271A5 JP 2023504271 A5 JP2023504271 A5 JP 2023504271A5 JP 2022532766 A JP2022532766 A JP 2022532766A JP 2022532766 A JP2022532766 A JP 2022532766A JP 2023504271 A5 JP2023504271 A5 JP 2023504271A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025260144A JP2026048871A (ja) | 2019-12-02 | 2025-12-17 | Ｐｄ－ｌ１に対する抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962942455P | 2019-12-02 | 2019-12-02 | |
| US62/942,455 | 2019-12-02 | ||
| PCT/US2020/062815 WO2021113307A2 (en) | 2019-12-02 | 2020-12-02 | Antibodies against pd-l1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260144A Division JP2026048871A (ja) | 2019-12-02 | 2025-12-17 | Ｐｄ－ｌ１に対する抗体およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023504271A JP2023504271A (ja) | 2023-02-02 |
| JPWO2021113307A5 JPWO2021113307A5 (https=) | 2024-11-15 |
| JP2023504271A5 true JP2023504271A5 (https=) | 2024-11-15 |
| JP7795459B2 JP7795459B2 (ja) | 2026-01-07 |
Family
ID=76222467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022532766A Active JP7795459B2 (ja) | 2019-12-02 | 2020-12-02 | Ｐｄ－ｌ１に対する抗体およびその使用方法 |
| JP2025260144A Pending JP2026048871A (ja) | 2019-12-02 | 2025-12-17 | Ｐｄ－ｌ１に対する抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260144A Pending JP2026048871A (ja) | 2019-12-02 | 2025-12-17 | Ｐｄ－ｌ１に対する抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230127123A1 (https=) |
| EP (1) | EP4069294A4 (https=) |
| JP (2) | JP7795459B2 (https=) |
| AU (1) | AU2020396896A1 (https=) |
| CA (1) | CA3159308A1 (https=) |
| WO (1) | WO2021113307A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| CN121620391A (zh) * | 2023-04-06 | 2026-03-06 | 金麦安博股份有限公司 | 用于治疗癌症的针对pd-l1和cd137的多特异性结合剂 |
| WO2025190373A1 (en) * | 2024-03-14 | 2025-09-18 | Topmunnity Therapeutics Taiwan Limited | Chimeric antigen receptor against programmed death ligand 1 (pd-l1) and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148321A1 (en) * | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| US8039218B2 (en) * | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| WO2006113747A2 (en) * | 2005-04-19 | 2006-10-26 | Prediction Sciences Llc | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| US20080280297A1 (en) * | 2005-07-15 | 2008-11-13 | The Trustees Of Columbia University In The City Of | Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia |
| US20110190157A1 (en) * | 2008-08-15 | 2011-08-04 | The Regents Of The University Of California | Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia |
| US20120178111A1 (en) * | 2009-09-23 | 2012-07-12 | Diamandis Eleftherios P | Methods and compositions for the detection of lung cancers |
| CA2886433C (en) * | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| WO2015061341A1 (en) * | 2013-10-21 | 2015-04-30 | Accuro Technologies Inc. | Double barrel syringe and method to use same for placement confirmation and joint space injection |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| BR112017013176A2 (en) * | 2014-12-19 | 2018-05-15 | Dana-Farber Cancer Institute Inc. | chimeric antigen receptors and methods for using them |
| WO2017143076A1 (en) * | 2016-02-16 | 2017-08-24 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptors and methods of use thereof |
| KR20190003938A (ko) * | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| EP3487883B1 (en) * | 2016-07-20 | 2023-01-04 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
| CN109906232B (zh) * | 2016-09-23 | 2023-11-07 | 马伦戈治疗公司 | 包含λ轻链和κ轻链的多特异性抗体分子 |
| JP7269167B2 (ja) * | 2016-10-14 | 2023-05-08 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | モジュラー四価二重特異性抗体プラットフォーム |
| AU2019235900B2 (en) * | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
-
2020
- 2020-12-02 EP EP20894953.7A patent/EP4069294A4/en active Pending
- 2020-12-02 JP JP2022532766A patent/JP7795459B2/ja active Active
- 2020-12-02 WO PCT/US2020/062815 patent/WO2021113307A2/en not_active Ceased
- 2020-12-02 US US17/780,389 patent/US20230127123A1/en active Pending
- 2020-12-02 CA CA3159308A patent/CA3159308A1/en active Pending
- 2020-12-02 AU AU2020396896A patent/AU2020396896A1/en active Pending
-
2025
- 2025-12-17 JP JP2025260144A patent/JP2026048871A/ja active Pending